146 related articles for article (PubMed ID: 15860250)
1. Nuclear hormone receptor co-repressors.
Baniahmad A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):89-97. PubMed ID: 15860250
[TBL] [Abstract][Full Text] [Related]
2. Steroid hormone receptors as targets for the therapy of breast and prostate cancer--recent advances, mechanisms of resistance, and new approaches.
Hoffmann J; Sommer A
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):191-200. PubMed ID: 15860262
[TBL] [Abstract][Full Text] [Related]
3. Co-repressors 2000.
Burke LJ; Baniahmad A
FASEB J; 2000 Oct; 14(13):1876-88. PubMed ID: 11023972
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of MAPK-signaling pathway promotes the interaction of the corepressor SMRT with the human androgen receptor and mediates repression of prostate cancer cell growth in the presence of antiandrogens.
Eisold M; Asim M; Eskelinen H; Linke T; Baniahmad A
J Mol Endocrinol; 2009 May; 42(5):429-35. PubMed ID: 19223455
[TBL] [Abstract][Full Text] [Related]
5. Analysis of ligand-specific co-repressor binding to the androgen receptor.
Gerlach C; Roell D; Baniahmad A
Methods Mol Biol; 2011; 776():199-223. PubMed ID: 21796529
[TBL] [Abstract][Full Text] [Related]
6. Alternative splicing determines the interaction of SMRT isoforms with nuclear receptor-DNA complexes.
Faist F; Short S; Kneale GG; Sharpe CR
Biosci Rep; 2009 Jun; 29(3):143-9. PubMed ID: 18752469
[TBL] [Abstract][Full Text] [Related]
7. ERRgamma suppresses cell proliferation and tumor growth of androgen-sensitive and androgen-insensitive prostate cancer cells and its implication as a therapeutic target for prostate cancer.
Yu S; Wang X; Ng CF; Chen S; Chan FL
Cancer Res; 2007 May; 67(10):4904-14. PubMed ID: 17510420
[TBL] [Abstract][Full Text] [Related]
8. Gene silencing by the thyroid hormone receptor.
Eckey M; Moehren U; Baniahmad A
Mol Cell Endocrinol; 2003 Dec; 213(1):13-22. PubMed ID: 15062570
[TBL] [Abstract][Full Text] [Related]
9. Macrophage/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway.
Zhu P; Baek SH; Bourk EM; Ohgi KA; Garcia-Bassets I; Sanjo H; Akira S; Kotol PF; Glass CK; Rosenfeld MG; Rose DW
Cell; 2006 Feb; 124(3):615-29. PubMed ID: 16469706
[TBL] [Abstract][Full Text] [Related]
10. Androgen receptor action in hormone-dependent and recurrent prostate cancer.
Agoulnik IU; Weigel NL
J Cell Biochem; 2006 Oct; 99(2):362-72. PubMed ID: 16619264
[TBL] [Abstract][Full Text] [Related]
11. Transcriptional repression by nuclear receptors: mechanisms and role in disease.
Love JD; Gooch JT; Nagy L; Chatterjee VK; Schwabe JW
Biochem Soc Trans; 2000; 28(4):390-6. PubMed ID: 10961926
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T
Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555
[TBL] [Abstract][Full Text] [Related]
13. Epigenetic corruption of VDR signalling in malignancy.
Abedin SA; Banwell CM; Colston KW; Carlberg C; Campbell MJ
Anticancer Res; 2006; 26(4A):2557-66. PubMed ID: 16886664
[TBL] [Abstract][Full Text] [Related]
14. Gene repression by nuclear hormone receptors.
Moehren U; Eckey M; Baniahmad A
Essays Biochem; 2004; 40():89-104. PubMed ID: 15242341
[TBL] [Abstract][Full Text] [Related]
15. Key targets of hormonal treatment of prostate cancer. Part 1: the androgen receptor and steroidogenic pathways.
Vis AN; Schröder FH
BJU Int; 2009 Aug; 104(4):438-48. PubMed ID: 19558559
[TBL] [Abstract][Full Text] [Related]
16. Regulatory processes affecting androgen receptor expression, stability, and function: potential targets to treat hormone-refractory prostate cancer.
Reddy GP; Barrack ER; Dou QP; Menon M; Pelley R; Sarkar FH; Sheng S
J Cell Biochem; 2006 Aug; 98(6):1408-23. PubMed ID: 16619263
[TBL] [Abstract][Full Text] [Related]
17. Nuclear hormone receptor co-regulators.
Khan OY; Nawaz Z
Curr Opin Drug Discov Devel; 2003 Sep; 6(5):692-701. PubMed ID: 14579519
[TBL] [Abstract][Full Text] [Related]
18. Hormone agonists and antagonists in the treatment of hormone sensitive breast and prostate cancer.
Nicholson RI; Walker KJ; Davies P
Cancer Surv; 1986; 5(3):463-86. PubMed ID: 3555778
[No Abstract] [Full Text] [Related]
19. Crossroads of estrogen receptor and NF-kappaB signaling.
Biswas DK; Singh S; Shi Q; Pardee AB; Iglehart JD
Sci STKE; 2005 Jun; 2005(288):pe27. PubMed ID: 15956359
[TBL] [Abstract][Full Text] [Related]
20. Stromal-epithelial cell interactions and androgen receptor-coregulator recruitment is altered in the tissue microenvironment of prostate cancer.
Cano P; Godoy A; Escamilla R; Dhir R; Onate SA
Cancer Res; 2007 Jan; 67(2):511-9. PubMed ID: 17234758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
